Last reviewed · How we verify
Blood samples for the analysis of sildenafil in plasma — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Blood samples for the analysis of sildenafil in plasma (Blood samples for the analysis of sildenafil in plasma) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Blood samples for the analysis of sildenafil in plasma TARGET | Blood samples for the analysis of sildenafil in plasma | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Blood samples for the analysis of sildenafil in plasma CI watch — RSS
- Blood samples for the analysis of sildenafil in plasma CI watch — Atom
- Blood samples for the analysis of sildenafil in plasma CI watch — JSON
- Blood samples for the analysis of sildenafil in plasma alone — RSS
Cite this brief
Drug Landscape (2026). Blood samples for the analysis of sildenafil in plasma — Competitive Intelligence Brief. https://druglandscape.com/ci/blood-samples-for-the-analysis-of-sildenafil-in-plasma. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab